key: cord-1013492-uwrcpu17
authors: Park, Jin-Woo; Kim, Byung-Jo
title: Lessons from COVID-19 in Clinical Neurology
date: 2021-12-30
journal: J Clin Neurol
DOI: 10.3988/jcn.2022.18.1.1
sha: 2cf24a9affb95a4c6b45ccb406a7b936ce606901
doc_id: 1013492
cord_uid: uwrcpu17

nan

Healthcare professionals should be aware of unusual neurological manifestations of COVID-19. Acute confusion could be the initial manifestation of SARS-CoV-2 infection, especially in elderly patients. Direct neuroinvasion of the virus and systemic inflammatory processes may play a role in acute confusion. 8 In another review of both large-scale studies and case reports of COVID-19-associated encephalitis and encephalopathy, the authors found that patients with encephalopathy/encephalitis were generally severely or critically ill, with almost all patients having lung abnormalities. 9 Some patients presented with the SARS-CoV-2 virus in their cerebrospinal fluid. 9 ACE2-related cell entry and central nervous system invasion, cytokine storm, coagulopathy, hypoxia, and molecular mimicry have all been suggested as possible culprits.

Guillain-Barré syndrome (GBS) is a relatively uncommon but profound neurological manifestation of COVID-19. A large cohort study found 6 cases of GBS among 10,881 newonset neurological complications associated with COVID-19. 1 The reported prevalence (approximately 0.06%) was higher than that observed in the general population (typically 0.001% to 0.004%). A case report also described a patient with facial diplegia, which occurred 2 weeks after SARS-CoV-2 infection. 10 GBS has also been reported after COVID-19 vaccination. In a review of 73 cases of GBS associated with COVID-19, the authors found that features were similar to classic postinfectious GBS, and suggested that they share the same immunemediated pathogenic mechanisms. 11 In contrast, a systemic review of 11 cases of Miller Fisher syndrome (MFS) found that different targets and mechanisms might be associated with MFS when COVID-19 precedes this syndrome, considering the relatively uncommon presence of antiganglioside antibodies in patients. 12 Lastly, JCN has published two case reports on COVID-19 vaccination-related neurological complications: 1) a rare case of vaccine-induced immune thrombotic thrombocytopenia 13 and 2) a possible case of COVID-19-vaccination-related cerebral venous sinus thrombosis. 14 The authors were only able to find a temporal relationship to explain this phenomenon. Vaccination-related neurological adverse events are tending to increase with the continuous increase of the vaccinated population. The great difficulty of demonstrating a direct causal relationship between vaccination and neurological complications makes it necessary to develop clinically useful biomarkers.

The COVID-19 pandemic has brought about a new era in healthcare. As our knowledge of the pandemic continues to evolve, the ongoing improvements in the methods for identifying neurological manifestations of COVID-19 will help us to develop effective healthcare strategies for dealing with new viruses. 

COVID-19 outcomes of 10,881 patients: retrospective study of neurological symptoms and associated manifestations (Philippine CORONA Study)

Salmaggi A. Recurrent transient ischemic attack in a young patient with CO-VID-19

Stroke in a feverish patient with COVID-19 infection and unknown endocarditis

Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review

Care process of recanalization therapy for acute stroke during the COVID-19 outbreak in South Korea

Epidemiologic characteristics and pre-hospital care of traumatic injuries during the COVID-19 pandemic in an emerging and developing country: a single tertiary centre experience

Neurological manifestations in patients with COVID-19: experiences from the Central Infectious Diseases Hospital in South Korea

Acute confusion as an initial presentation of SARS-CoV-2 infection

Encephalopathy in patients with CO-VID-19: a review

Facial diplegia: a rare subtype of Guillain-Barré syndrome in a patient with minimally symptomatic COVID-19

Guillain-Barré syndrome spectrum associated with COVID-19: an up-todate systematic review of 73 cases

Miller Fisher syndrome in patients with severe acute respiratory syndrome coronavirus 2 infection: a systematic review

Vaccine-induced immune thrombotic thrombocytopenia: first case report in South Korea

Cerebral venous sinus thrombosis after Pfizer-BioNTech COVID-19 (BNT162b2) vaccination

The authors have no potential conflicts of interest to disclose.

None